Molecular diagnosis is performed at the gene level with nucleic acids as the object for detection, with high sensitivity and accuracy.

Stay up-to-date with the latest happenings in the rapidly evolving field of In Vitro Diagnostics (IVD) in China.

Two powerhouses in pharma and medtech are working together to help people with diabetes better manage their condition. Abbott Laboratories and Sanofi will collaborate to integrate glucose sensing and insulin delivery technologies.

A Danish and Taiwanese company has won Australia’s Good Design Award for a portable diagnostic device—small enough to fit in a camera case—that allows diagnosis of infectious diseases on the spot from a single drop of blood.

Looking east to the Pacific, there is Los Angeles, known as the "City of Angels." On the evening of 7 August, at the 71st American Association for Clinical Chemistry (AACC) in Los Angeles, the North American Chinese Clinical Chemists Associa

Quidel reported after the close of the market Thursday that its second quarter revenues rose 5 percent year over year due primarily to growth in the firm's rapid immunoassay business. Growth in molecular and specialized diagnostic solutions

Bio-Rad Laboratories reported after the close of the market Thursday that its second quarter revenues decreased approximately 1 percent year over year.

Coriell Life Sciences and global professional services firm KPMG said today that they have entered into a partnership with to provide pharmacogenomics data to clinicians at the point of care. Thermo Fisher Scientific is contributing genetic

Expedeon reported today an 18 percent increase in second quarter revenues driven in part by sales generated by recently acquired reagent maker TGR Biosciences.

Bio-Techne said today that its fiscal 2019 fourth quarter revenues rose 6 percent over fiscal Q4 2018.

Revenues from BD's medical segment were $2.31 billion during the quarter, an increase of 3 percent from $2.25 billion last year driven by medication management solutions, medication delivery solutions, and pharmaceutical systems units.

Genomenon has entered the Chinese market by forming a partnership with Shanghai Shanyi Biological Technology Co., a provider of sequencing interpretation, variant validation, and other molecular technology services.